Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05998122 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study

Name: Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study — clinical trial record (NCT05998122)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorThe First Hospital of Jilin University

Started2023-09-01

View on ClinicalTrials.gov ↗

The First Hospital of Jilin University

86 trials monitored

See 2 trials at risk

Colorectal Cancer

2,904 trials monitored

See 127 trials at risk

Previously, preliminary results, from a subgroup analysis of STARS-RC03 (NCT04906044) conducted by our research team, showed that the 6-cycles consolidation chemotherapy combining with anti-PD-1 therapy had a better tumor regression advantage with a restricted safety profile contrasted with 3-cycle counterparts. Herein, we designed this study to further evaluate the short-term efficacy (such as pCR rate, R0 resection rate, etc.) and long-term survival (including DFS, OS, etc.) of 6-cycles consolidation therapy.

Trial Details

NCT Number	NCT05998122
Lead Sponsor	The First Hospital of Jilin University
Conditions	Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1
Enrollment	45 participants
Start Date	2023-09-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2023-08-18